Oligometastases: the art of providing metastases-directed therapy in prostate cancer

Fijs W B van Leeuwen^{1

2}, Henk G van der Poel³

Affiliations

¹ Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, Netherlands. f.w.b.van_leeuwen@lumc.nl.
² Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. f.w.b.van_leeuwen@lumc.nl.
³ Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

Comment

Fijs W B van Leeuwen et al. Nat Rev Urol. 2022 May.

. 2022 May;19(5):259-260.

doi: 10.1038/s41585-022-00570-9.

Fijs W B van Leeuwen^{1

2}, Henk G van der Poel³

¹ Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, Netherlands. f.w.b.van_leeuwen@lumc.nl.
² Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. f.w.b.van_leeuwen@lumc.nl.
³ Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

No abstract available

Comment on

Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial.
Hölscher T, Baumann M, Kotzerke J, Zöphel K, Paulsen F, Müller AC, Zips D, Koi L, Thomas C, Löck S, Krause M, Wirth M, Lohaus F. Hölscher T, et al. Eur Urol Oncol. 2022 Feb;5(1):44-51. doi: 10.1016/j.euo.2021.10.002. Epub 2021 Nov 14. Eur Urol Oncol. 2022. PMID: 34785189 Clinical Trial.

1. Weichselbaum, R. R. & Hellman, S. Oligometastases revisited. Nat. Rev. Clin. Oncol. 8, 378–382 (2011). - DOI
1. Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395, 1208–1216 (2020). - DOI
1. Mazonne, E. et al. Diagnostic value, oncologic outcomes, and safety profile of image-guided surgery technologies during robot-assisted lymph node dissection with sentinel node biopsy for prostate cancer. J. Nucl. Med. 62, 1363–1371 (2021). - DOI
1. Horn, T. et al. Single lesion on prostate-specific membrane antigen-ligand positron emission tomography and low prostate-specific antigen are prognostic factors for a favorable biochemical response to prostate-specific membrane antigen-targeted radioguided surgery in recurrent prostate cancer. Eur. Urol. 76, 517–523 (2019). - DOI
1. Mazzola, R. et al. Metastasis-directed therapy (SBRT) guided by PET-CT ¹⁸F-choline versus PET-CT ⁶⁸Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness. Clin. Genitourin. Cancer 19, 230–236 (2021). - DOI